Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Jumper who wrote (1379)	12/28/1997 9:27:00 PM
From: Bruce Rosen	Read Replies (1) \| Respond to of 7041

This from another board: <<To Asensio- What do you know about pharmacokinetics? Have you ever heard of the concept? This explains how different formulations of the same drug can interact in entirely different ways on the human body. So, technically speaking, if you had a short-acting preparation of nifedipine (a calcium-channel blocker) and compared it to a long-acting preparation of the same drug, such as Procardia XL or Adalat CC, you could get two entirely different results. It's kind of like comparing APPLES and ORANGES, if you get my drift. Why is it that hypertensive patients treated with short-acting preparations of calcium channel blockers have shown increased morbidity and mortality but the long-acting preparations have shown just the opposite effect over time? Procardia XL is still a big selling anti-hypertensive for Pfizer and Adalat CC is Bayer's successful long-acting version of the same drug. So, perhaps this is all just a big conspiracy designed by the major drug companies to protect their billion dollar interests in the hypertensive arena for long-acting calcium channel blockers or perhaps it is all just simple pharmacokinetics? Hey, Asensio, have you ever taken a course in pharmacokinetics? Perhaps you should and I'll pay for it---after all, you're the one who keeps ranting and raving about an old IV preparation of phentolamine mesylate and how it matches Zonagen's new oral version of the same drug. How do you know that the pharmacokinetic activities of these two entirely different formulations is exactly the same? How do you know that you are not comparing APPLES and ORANGES? Have you done a detailed analysis of the pharmacokinetic profiles of these two different preparations and how they each exert their effect on the human body? Can you even tell me if either of these drugs acts by ZERO ORDER, FIRST ORDER or SECOND ORDER kinetics? Why don't you explain to all the readers on this board in full detail the exact reason why a short-acting oral version of nifedipine is bad but a long-acting oral version of the same drug is good. I'm sure we would all like to read your detailed scientific analysis because you and your staff are all such geniuses. Until you can prove to me that you understand the concept of pharmacokinetics then I will consider YOU the FRAUD and NOT Zonagen. P.S. Please include tables and graphs with your comprehensive report on nifedipine. Thank you. >>